Answers are grounded in this paper and cite their sources.
In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
No takes yet. Share an insight, caveat, or question.
Paz‐Ares et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: